市場調查報告書
商品編碼
1392144
數位病理學市場 - 按產品、應用、最終用途 - 全球預測,2023-2032 年Digital Pathology Market - By Product, Application, End-use - Global Forecast, 2023-2032 |
在產業領導者不斷推出和創新的推動下,2023 年至 2032 年全球數位病理市場CAGR將達到 10.4%。先驅公司對成像技術、人工智慧驅動的分析和基於雲端的解決方案進步的不懈追求重塑了病理學實踐。例如,2023年11月,歐洲領先的解剖病理學資訊系統供應商Dedalus Group與以人工智慧驅動的癌症診斷而聞名的Ibex Medical Analytics合作,推出了由人工智慧驅動的先進數位病理學解決方案,使用於癌症診斷。此整合解決方案將 Ibex 的 Galen (TM) 平台與 Dedalus 的綜合數位病理學解決方案相結合,為解剖病理學實驗室數位化樹立了開創性的基準。
尖端產品的推出提高了診斷準確性,簡化了工作流程,並支援遠端存取醫療資料,徹底改變了醫療保健服務。數位病理學市場需求的增加反映了該行業對技術突破的反應能力,強調了創新在提高診斷精度和改變全球病理學服務格局方面的關鍵作用。
數位病理學市場的總體佔有率根據產品、最終用途和地區進行分類。
從 2023 年到 2032 年,軟體領域將經歷重大發展。先進的數位病理學軟體將徹底改變醫療診斷,提供精確性、可擴展性和遠端可訪問性。這些軟體解決方案利用人工智慧、機器學習和影像分析來增強病理工作流程,從而實現更快、更準確的診斷。隨著全球醫療機構的採用激增,數位病理學市場佔有率見證了對軟體的需求不斷增加,這些軟體為病理學家提供了全面的工具,提高了效率並幫助複雜的疾病檢測和治療計劃。
2023年至2032年,醫院領域的數位病理市場規模將出現顯著的CAGR。為了改善病患護理,醫院擴大採用數位病理技術。這些創新簡化了工作流程,提供對病理資料的遠端訪問,並增強了醫療保健專業人員之間的協作。數位病理工具使醫院能夠加快診斷速度、提高準確性並促進與現有醫療保健系統的無縫整合。人們對這些好處的日益認知推動了全球醫療機構對數位病理學市場需求的不斷成長。
歐洲數位病理學產業從 2023 年到 2032 年將呈現出值得稱讚的CAGR。歐洲國家正在採用數位病理學解決方案來提高診斷準確性、簡化工作流程並改善患者護理。政府支持創新醫療技術的舉措以及遠端存取病理資料的需求推動了這一激增。隨著該地區日益強調精準醫療和醫療保健的進步,歐洲醫療機構對數位病理系統的需求持續穩定成長。
例如,2023 年 11 月,荷蘭先驅公司飛利浦於 2017 年推出了 FDA 批准的用於初級診斷的數位病理切片掃描儀,成為數位病理領域的開拓者。根據 KLAS Research 最新題為「美國數位病理學 2023」績效洞察的報告,飛利浦因其在美國境內外擁有「最廣泛的初級診斷客戶群之一」而被認可,這得益於其值得稱讚的數字病理解決方案。
Global Digital Pathology Market will witness 10.4% CAGR between 2023 and 2032, propelled by continuous launches and innovations by industry leaders. The relentless pursuit of advancements in imaging technologies, AI-driven analysis, and cloud-based solutions by pioneering companies reshapes pathology practices. For instance, in November 2023, Dedalus Group, a leading provider of anatomic pathology information systems in Europe, in collaboration with Ibex Medical Analytics, known for AI-driven cancer diagnostics, introduced an advanced Digital Pathology Solution powered by AI for cancer diagnosis. This integrated solution, merging Ibex's Galen™ platform with comprehensive Digital Pathology Solution by Dedalus, sets a pioneering benchmark in anatomic pathology lab digitization.
Cutting-edge launches enhance diagnostic accuracy, streamline workflows, and enable remote access to medical data, revolutionizing healthcare delivery. This heightened digital pathology market demand reflects the industry's responsiveness to technological breakthroughs, emphasizing the pivotal role of innovation in elevating diagnostic precision and transforming the landscape of pathology services globally.
The overall Digital Pathology Market share is classified based on product, end-use, and region.
Software segment will undergo significant development from 2023 to 2032. Advanced digital pathology software revolutionizes medical diagnostics, offering precision, scalability, and remote accessibility. These software solutions leverage AI, machine learning, and image analysis to enhance pathology workflows, enabling faster and more accurate diagnoses. With a surge in adoption across healthcare facilities worldwide, the digital pathology market share witnesses increased demand for software that empowers pathologists with comprehensive tools, improving efficiency and aiding in complex disease detection and treatment planning.
Digital pathology market size from the hospitals segment will register a noteworthy CAGR from 2023 to 2032. With a focus on improving patient care, hospitals are increasingly adopting digital pathology technologies. These innovations streamline workflows, offer remote access to pathology data, and enhance collaboration among healthcare professionals. Digital pathology tools empower hospitals to expedite diagnoses, improve accuracy, and facilitate seamless integration with existing healthcare systems. The growing recognition of these benefits fuels the escalating digital pathology market demand among healthcare institutions globally.
Europe digital pathology industry will showcase a commendable CAGR from 2023 to 2032. European countries are embracing digital pathology solutions to enhance diagnostic accuracy, streamline workflows, and improve patient care. This surge is bolstered by government initiatives supporting innovative healthcare technologies and the need for remote access to pathology data. As the region increasingly emphasizes precision medicine and advancements in healthcare, the demand for digital pathology systems continues to grow steadily across European healthcare facilities.
For instance, in November 2023, Philips, the pioneering company from the Netherlands that debuted an FDA-approved digital pathology slide scanner for primary diagnostic use in 2017, stood as a trailblazer in the realm of digital pathology. According to the most recent KLAS Research report titled 'U.S. Digital Pathology 2023' Performance Insights, Philips was recognized for possessing "one of the most extensive customer bases for primary diagnosis," both within and beyond the borders of the United States, owing to its commendable digital pathology solutions.